COCH PE Ratio & Valuation,Is COCH Overvalued

COCH Relative Valuation

COCH's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, COCH is overvalued; if below, it's undervalued.

Historical Valuation

Envoy Medical Inc (COCH) is now in the Fair zone, suggesting that its current forward PS ratio of 110.40 is considered Fairly compared with the five-year average of -1.84. The fair price of Envoy Medical Inc (COCH) is between 0.09 to 1.17 according to relative valuation methord.

Relative Value

Fair Zone

0.09-1.17

Current Price：0.79

Fair

-0.75

0.00

EV/EBITDA

Envoy Medical Inc. (COCH) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -1.26. The thresholds are as follows: Strongly Undervalued below -5.36, Undervalued between -5.36 and -3.31, Fairly Valued between 0.79 and -3.31, Overvalued between 0.79 and 2.84, and Strongly Overvalued above 2.84. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-0.95

EV/EBIT

Envoy Medical Inc. (COCH) has a current EV/EBIT of -0.95. The 5-year average EV/EBIT is -2.01. The thresholds are as follows: Strongly Undervalued below -5.87, Undervalued between -5.87 and -3.94, Fairly Valued between -0.08 and -3.94, Overvalued between -0.08 and 1.85, and Strongly Overvalued above 1.85. The current Forward EV/EBIT of -0.95 falls within the Historic Trend Line -Fairly Valued range.

110.40

Envoy Medical Inc. (COCH) has a current PS of 110.40. The 5-year average PS is 105.73. The thresholds are as follows: Strongly Undervalued below -83.48, Undervalued between -83.48 and 11.13, Fairly Valued between 200.34 and 11.13, Overvalued between 200.34 and 294.94, and Strongly Overvalued above 294.94. The current Forward PS of 110.40 falls within the Historic Trend Line -Fairly Valued range.

-0.84

P/OCF

Envoy Medical Inc. (COCH) has a current P/OCF of -0.84. The 5-year average P/OCF is -1.34. The thresholds are as follows: Strongly Undervalued below -4.15, Undervalued between -4.15 and -2.74, Fairly Valued between 0.07 and -2.74, Overvalued between 0.07 and 1.47, and Strongly Overvalued above 1.47. The current Forward P/OCF of -0.84 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Envoy Medical Inc. (COCH) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.

Envoy Medical Inc (COCH) has a current Price-to-Book (P/B) ratio of -2.54. Compared to its 3-year average P/B ratio of -6.85 , the current P/B ratio is approximately -62.90% higher. Relative to its 5-year average P/B ratio of -6.22, the current P/B ratio is about -59.11% higher. Envoy Medical Inc (COCH) has a Forward Free Cash Flow (FCF) yield of approximately -73.67%. Compared to its 3-year average FCF yield of -52.93%, the current FCF yield is approximately 39.18% lower. Relative to its 5-year average FCF yield of -52.93% , the current FCF yield is about 39.18% lower.

-2.54

P/B

Median3y

-6.85

Median5y

-6.22

-73.67

FCF Yield

Median3y

-52.93

Median5y

-52.93

Competitors Valuation Multiple

The average P/S ratio for COCH's competitors is 18.69, providing a benchmark for relative valuation. Envoy Medical Inc Corp (COCH) exhibits a P/S ratio of 110.40, which is 490.55% above the industry average. Given its robust revenue growth of -25.00%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of COCH decreased by 43.68% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -10.64K to -15.43K.

The secondary factor is the Revenue Growth, contributed -25.00%to the performance.

Overall, the performance of COCH in the past 1 year is driven by Margin Expansion. Which is more sustainable.

-25.00%

56.00K → 42.00K

Revenue Growth

45.01%

-10.64K → -15.43K

Margin Expansion

-63.69%

-1.62 → -0.59

P/E Change

-43.68%

1.43 → 0.81

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Envoy Medical Inc (COCH) currently overvalued or undervalued?

What is Envoy Medical Inc (COCH) fair value?

COCH's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Envoy Medical Inc (COCH) is between 0.09 to 1.17 according to relative valuation methord.

How does COCH's valuation metrics compare to the industry average?

What is the current P/B ratio for Envoy Medical Inc (COCH) as of Dec 15 2025?

As of Dec 15 2025, Envoy Medical Inc (COCH) has a P/B ratio of -2.54. This indicates that the market values COCH at -2.54 times its book value.

What is the current FCF Yield for Envoy Medical Inc (COCH) as of Dec 15 2025?

As of Dec 15 2025, Envoy Medical Inc (COCH) has a FCF Yield of -73.67%. This means that for every dollar of Envoy Medical Inc’s market capitalization, the company generates -73.67 cents in free cash flow.

What is the current Forward P/E ratio for Envoy Medical Inc (COCH) as of Dec 15 2025?

As of Dec 15 2025, Envoy Medical Inc (COCH) has a Forward P/E ratio of -0.75. This means the market is willing to pay $-0.75 for every dollar of Envoy Medical Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Envoy Medical Inc (COCH) as of Dec 15 2025?

As of Dec 15 2025, Envoy Medical Inc (COCH) has a Forward P/S ratio of 110.40. This means the market is valuing COCH at $110.40 for every dollar of expected revenue over the next 12 months.

COCH Valuation